Karin Schölin Bywall
Karin Schölin Bywall
MSc Public Health
Karin Schölin Bywall is a PhD student in the IMI-funded PREFER project. The project is aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.
Karin Schölin Bywall has a master of science in public health from Mälardalen University where she also teached in public health.
Phone: +46 18 471 62 49
Recently in the media
- Patienters syn på att inkluderas i forskning om läkemedel
Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis
Part of the patient - patient-centered outcomes research, 2018.
Mapping benefit-risk decision-making processes and identifying decision points with the potential to include patient preference information throughout the medical product lifecycle
Part of Pharmacoepidemiology and Drug Safety, p. 206-206, 2018.
Stakeholder Perspectives On The Integration Of Patient Preferences In The Medical Product Life Cycle: A Multimethod Approach
Part of Value in Health, p. A689-A689, 2017.
Rheumatoid Arthritis Patients’ Perspectives On The Value Of Patient Preferences In Regulatory Decision-Making During Drug Development: A Qualitative Study
Part of Value in Health, p. A540-A540, 2017.
Conditions And Contextual Factors That Influence The Utility And Application Of Patient Preference Studies: A Study Combining Literature And Focus Groups
Part of Value in Health, p. A690-A691, 2017.
We are investigating risk information from serval perspectives.
Giving patients a voice in drug development
PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development
Karin Schölin Bywall will look at how rheumatoid arthritis patient preferences can provide added value in regulatory decision making in the drug development process.
Methodology, rheumatoid arthritis and patient involvement
Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.